Abstract
UNLABELLED: Automated seizure detection devices are increasingly plausible tools for epilepsy trials, but no device is perfect. We used CHOCOLATES, a realistic seizure diary simulator, to examine how device sensitivity and false alarm rate (FAR) affect regression-to-the-mean (RTM) and placebo median percentage change (MPC) in a simulated randomized trial design. For each device condition, 100,000 potential participants were generated; eligibility was assessed during a 2-month baseline, followed by a 3-month test period. With FAR fixed at 0, reducing sensitivity from 100% to 10% increased the fraction of eligible participants exhibiting RTM from 38.2% to 64.8% and increased placebo MPC from 14.7% to 48.1%. With sensitivity fixed at 100% and expected FAR correction, increasing FAR from 0 to 1 alarm/day increased RTM from 38.2% to 53.2% and placebo MPC from 14.7% to 31.3%. Imperfect seizure detection can therefore change the apparent placebo response expected from RTM.
SHORT SUMMARY FOR TABLE OF CONTENTS: In simulated epilepsy trials, imperfect seizure detection altered regression to the mean and placebo median percentage change. Trial planning should model detector sensitivity and false alarm rate before device-derived seizure counts are used as endpoints.
